Chronic myeloid leukaemia treated by allogeneic bone marrow transplantation from histocompatible sibling donors – an invariably fatal malignancy rendered highly curable

Abstract

Abstract Twenty‐eight patients aged 16–50 years with chronic myeloid leukaemia (CML) underwent allogeneic bone marrow transplantation (BMT) using human leukocyte antigen (HLA)‐identical sibling donors. Of the 28 patients, 21 were in chronic phase, five were in accelerated phase and two were in blast phase at the time of BMT. Twenty‐three of the patients survived more than 63–2187 days after BMT, 21 in continuous complete remission and two with haemato‐logic relapse of CML. Two patients died of interstitial pneumonitis and one died of relapsed CML, cerebral aspergillosis and cytomegalovirus enterocolitis. The overall probability of survival at six years was 78%± 9% (mean ± standard error) and..